Racial and Ethnic Differences in Restarting Antiplatelet Therapy in Patients with Primary Intracranial Hemorrhage: a Systematic Review and Meta-analysis

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2024 Aug 10

PMID 39127615

Authors

Xuechang Wang

Ting Chen

Junning Zhou

Yuan Qin

Affiliations

Soon will be listed here.

Abstract

Background: There has long been clinical disagreement over the resumption of antiplatelet therapy in patients with primary intracranial hemorrhage (ICH). This meta-analysis aimed to systematically evaluate the efficacy and safety of restarting antiplatelet therapy after ICH among different races and ethnicities.

Methods: All relevant medical studies involving adults with antiplatelet-associated ICH published in PubMed, The Cochrane Library and Chinese National Knowledge Infrastructure from inception to March 2024 were sourced. Outcome measures were thromboembolic events (stroke and myocardial infarction) and recurrence of ICH. After assessing study heterogeneity and publication bias, we performed a meta-analysis using random-effects model to assess the strength of association between resumption of antiplatelet therapy and our outcomes.The review was not registered and the review protocol was not prepared.

Results: Thirty-five studies were included, with 9758 ICH patients. Subgroup analysis revealed that restarting antiplatelet therapy was associated with a significantly higher risk of recurrence or aggravation of cerebral hemorrhage in Asians[OR = 1.48, 95% CI (1.13-1.94), P = 0.004]; in Caucasians, on the contrary, reinitiation of antiplatelet therapy was not associated with a significantly higher risk of recurrence or aggravation of cerebral hemorrhage [OR = 0.85, 95% CI (0.67-1.06), P = 0.149]. Reinitiation of antiplatelet therapy was associated with a significantly lower risk of cerebral infarction [OR = 0.61, 95% CI (0.39-0.96), P = 0.033]. Restarting antiplatelet therapy after cerebral hemorrhage was not associated with a higher incidence rate of mortality [OR = 0.79, 95% CI (0.57, 1.08), P = 0.138], myocardial infarction [OR = 2.40, 95%CI (0.53,10.79), P = 0.253], hemiparesis [OR = 0.38, 95%CI (0.03,4.81), P = 0.451], neurological deficit [OR = 0.86,95%CI(0.32,2.33),P = 0.766].

Conclusion: Reinstitution of antiplatelet therapy after ICH was associated with a lower risk of thromboembolic complications.Resumption of antiplatelet therapy was not associated with a higher incidence of cerebral hemorrhage in Caucasians, but may be associated with a higher risk of cerebral hemorrhage recurrence in Asian populations.

References

Tugcu B, Tanriverdi O, Baydin S, Hergunsel B, Gunaldi O, Ofluoglu E . Can recurrence of chronic subdural hematoma be predicted? A retrospective analysis of 292 cases. J Neurol Surg A Cent Eur Neurosurg. 2013; 75(1):37-41. DOI: 10.1055/s-0032-1330961. View

Torihashi K, Sadamasa N, Yoshida K, Narumi O, Chin M, Yamagata S . Independent predictors for recurrence of chronic subdural hematoma: a review of 343 consecutive surgical cases. Neurosurgery. 2008; 63(6):1125-9. DOI: 10.1227/01.NEU.0000335782.60059.17. View

Suzuki S, Sano K, Handa H, Asano T, Tamura A, Yonekawa Y . Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study. Neurol Res. 1989; 11(2):79-88. DOI: 10.1080/01616412.1989.11739867. View

Bamford J, Sandercock P, Warlow C, Slattery J . Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1989; 20(6):828. DOI: 10.1161/01.str.20.6.828. View

Kernan W, Ovbiagele B, Black H, Bravata D, Chimowitz M, Ezekowitz M . Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(7):2160-236. DOI: 10.1161/STR.0000000000000024. View

Brennan P, Kolias A, Joannides A, Shapey J, Marcus H, Gregson B . The management and outcome for patients with chronic subdural hematoma: a prospective, multicenter, observational cohort study in the United Kingdom. J Neurosurg. 2017; :1-8. DOI: 10.3171/2016.8.JNS16134.test. View

Hop J, Rinkel G, Algra A, Berkelbach van der Sprenkel J, van Gijn J . Randomized pilot trial of postoperative aspirin in subarachnoid hemorrhage. Neurology. 2000; 54(4):872-8. DOI: 10.1212/wnl.54.4.872. View

Pantoni L . Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010; 9(7):689-701. DOI: 10.1016/S1474-4422(10)70104-6. View

Teo K, Mahboobani N, Lee R, Siu C, Cheung R, Ho S . Warfarin associated intracerebral hemorrhage in Hong Kong Chinese. Neurol Res. 2013; 36(2):143-9. DOI: 10.1179/1743132813Y.0000000275. View

10.

Bejot Y, Cordonnier C, Durier J, Aboa-Eboule C, Rouaud O, Giroud M . Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. Brain. 2013; 136(Pt 2):658-64. DOI: 10.1093/brain/aws349. View

11.

Toyoda K, Yasaka M, Nagata K, Nagao T, Gotoh J, Sakamoto T . Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage. The Bleeding with Antithrombotic Therapy (BAT) Retrospective Study. Cerebrovasc Dis. 2008; 27(2):151-9. DOI: 10.1159/000177924. View

12.

Guha D, Coyne S, Loch Macdonald R . Timing of the resumption of antithrombotic agents following surgical evacuation of chronic subdural hematomas: a retrospective cohort study. J Neurosurg. 2015; 124(3):750-9. DOI: 10.3171/2015.2.JNS141889. View

13.

Okano A, Oya S, Fujisawa N, Tsuchiya T, Indo M, Nakamura T . Analysis of risk factors for chronic subdural haematoma recurrence after burr hole surgery: optimal management of patients on antiplatelet therapy. Br J Neurosurg. 2013; 28(2):204-8. DOI: 10.3109/02688697.2013.829563. View

14.

Li L, Poon M, Samarasekera N, Perry L, Moullaali T, Rodrigues M . Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurol. 2021; 20(6):437-447. PMC: 8134058. DOI: 10.1016/S1474-4422(21)00075-2. View

15.

Cuadrado-Godia E, Dwivedi P, Sharma S, Ois Santiago A, Roquer Gonzalez J, Balcells M . Cerebral Small Vessel Disease: A Review Focusing on Pathophysiology, Biomarkers, and Machine Learning Strategies. J Stroke. 2018; 20(3):302-320. PMC: 6186915. DOI: 10.5853/jos.2017.02922. View

16.

Snyder M, Ironside N, Kumar J, Doan K, Kellogg R, Provencio J . Antiplatelet therapy and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Neurosurg. 2021; 137(1):95-107. DOI: 10.3171/2021.7.JNS211239. View

17.

Garcia-Yebenes I, Sobrado M, Zarruk J, Castellanos M, Perez de la Ossa N, Davalos A . A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke. Stroke. 2010; 42(1):196-203. DOI: 10.1161/STROKEAHA.110.600452. View

18.

Okamura A, Kawamoto Y, Sakoda E, Murakami T, Hara T . Evaluation of recurrence factors and Gorei-san administration for chronic subdural hematoma after percutaneous subdural tapping. Hiroshima J Med Sci. 2014; 62(4):77-82. View

19.

Abboud T, Duhrsen L, Gibbert C, Westphal M, Martens T . Influence of antithrombotic agents on recurrence rate and clinical outcome in patients operated for chronic subdural hematoma. Neurocirugia (Astur : Engl Ed). 2017; 29(2):86-92. DOI: 10.1016/j.neucir.2017.09.006. View

20.

Pasquini M, Charidimou A, van Asch C, Baharoglu M, Samarasekera N, Werring D . Variation in restarting antithrombotic drugs at hospital discharge after intracerebral hemorrhage. Stroke. 2014; 45(9):2643-8. DOI: 10.1161/STROKEAHA.114.006202. View